Cohort 8.0 founders Garland Surgical have been awarded up to €1.4 million in grant funding by Malta Enterprise.

We are incredibly excited to bring you some fantastic news from Cohort 8.0 founders Garland Surgical. Garland, who are developing a revolutionary longer-lasting hip replacement - the MaltaHip have been approved for up to €1.4 million in grant funding by Malta Enterprise - the economic development agency for Malta.

Aimed at helping Garland push the MaltaHip towards regulatory approval and market launch, Malta Enterprise's grant offering also includes laboratory space at the Malta Life Sciences Park, key for further research and development.

We are tremendously proud to see the confidence and support that has been generated in the MaltaHip project and look forward to seeing the continued journey towards fully-fledged public use.

To read the full LinkedIn post from Garland Surgical, use the link here.

Share: Share on Twitter Share on LinkedIn

08 May 2025 | Cohort Successes

Garland Surgical's (Cohort 8.0) game-changing MaltaHip has been featured in notable scientific...

Read Article SHARE Share on Twitter Share on LinkedIn

06 May 2025 | Cohort Successes

Cohort 5.0 alumni ChangeMaker3D have received a nomination for the 2025 Digital Construction Awards...

Read Article SHARE Share on Twitter Share on LinkedIn

04 Apr 2025 | Cohort Successes

BetaDen Accelerate Cohort 2.0 alumni Utelize picked up a win in the 'Enterprise IoT eSim Product'...

Read Article SHARE Share on Twitter Share on LinkedIn